All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Clinical comparison

Linaclotide (Linzess) vs Romiplostim (Nplate)

An educational, source-based comparison of Linaclotide (Linzess) and Romiplostim (Nplate) — how each peptide works, what it's researched for, and what to know before going deeper.

GC-C Agonist · Gastrointestinal
Linaclotide (Linzess)

Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.

Mechanism

14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.

Research areas
  • IBS-C
  • Chronic idiopathic constipation
  • Functional constipation in children
Considerations
  • FDA-approved.
  • Contraindicated in children <2 years; diarrhea common.
Full Linaclotide (Linzess) profile →
TPO Mimetic · Hematology
Romiplostim (Nplate)

Thrombopoietin-receptor peptibody for immune thrombocytopenia.

Mechanism

Peptibody (Fc-peptide fusion) containing TPO receptor-binding peptide domains that activate c-Mpl on megakaryocytes, stimulating platelet production without competing with endogenous TPO.

Research areas
  • Chronic immune thrombocytopenia (ITP)
  • Pediatric ITP
  • Hematopoietic syndrome of acute radiation
Considerations
  • FDA-approved.
  • Reticulin fiber deposition in bone marrow; thrombosis risk with over-correction.
Full Romiplostim (Nplate) profile →

Linaclotide (Linzess) vs Romiplostim (Nplate) — Key differences

  • Class: Linaclotide (Linzess) is classified as GC-C Agonist · Gastrointestinal, while Romiplostim (Nplate) is TPO Mimetic · Hematology.
  • Primary research focus: Linaclotide (Linzess)ibs-c; Romiplostim (Nplate)chronic immune thrombocytopenia (itp).
  • Tag: FDA-Approved · GI vs FDA-Approved · Hematology.

Related comparisons